Definitive Healthcare Corp. - DH STOCK NEWS

Definitive Healthcare (Nasdaq: DH) has announced the granting of inducement awards to its newly hired senior leader. The company's Human Capital Management and Compensation Committee approved inducement awards for Jeff Moyer, who joins as SVP of Growth and Sales Operations.

The awards include 364,432 time-based restricted stock units (RSUs), effective April 3, 2025. The RSUs will vest according to the following schedule: 25% on April 1, 2026, with the remaining amount vesting in quarterly installments of 6.25% over the subsequent three years. These awards were granted under Definitive Healthcare's 2023 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Definitive Healthcare (Nasdaq: DH) announced inducement awards for two newly hired senior leaders. The company granted 172,414 time-based restricted stock units (RSUs) to Kate Hastings, the new Chief Customer Officer, and 1,018,330 RSUs to Benjamin Graboske, the new EVP, Technology, Engineering and Chief Data Officer, both effective March 3, 2025.

The awards, granted under Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan, feature a vesting schedule where 25% vests initially (February 1, 2026 for Hastings; April 1, 2026 for Graboske), with the remainder vesting quarterly at 6.25% over three years, subject to continued employment.

Definitive Healthcare (DH) reported mixed Q4 and full-year 2024 results. Q4 revenue declined 6% to $62.3 million, while full-year revenue slightly increased to $252.2 million. The company recorded significant goodwill impairment charges of $97.1 million in Q4 and $688.9 million for the full year.

Q4 highlights include: Net Loss of $(84.7) million, Adjusted Net Income of $12.6 million, and Adjusted EBITDA of $17.5 million (28% margin). Full-year metrics showed improvement in cash flow operations, up 41% to $58.2 million, and Unlevered Free Cash Flow increased 6% to $72.5 million.

The company announced Casey Heller will become CFO effective June 2, 2025. For 2025, DH projects revenue between $230.0-$240.0 million and Adjusted EBITDA of $61.0-$65.0 million with 26-28% margin.

Definitive Healthcare (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the upcoming Raymond James 2025 Institutional Investors Conference. CEO Kevin Coop and CFO Rick Booth will deliver a presentation on Tuesday, March 4, 2025, at 3:25 p.m. Eastern Time.

Investors and interested parties can access the live presentation through a webcast available on the Events page of Definitive Healthcare's investor relations website at https://ir.definitivehc.com/. A recorded version of the presentation will be accessible for a time after the event.

Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence company, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results.

Investors can access the live audio webcast through the company's Investor Relations website at ir.definitivehc.com. A dial-in option will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). A replay will be accessible through March 29, 2025, using 800-645-7964 or 757-849-6722 with passcode 1765#.

Definitive Healthcare (Nasdaq: DH) has been named among Built In's 100 Best Places to Work in Boston for 2025. The recognition, which includes companies of various sizes and both remote-first and traditional employers, highlights DH's commitment to employee satisfaction and workplace culture.

CEO Kevin Coop emphasized the company's focus on making an impact in healthcare and fostering a culture of innovation where employees are empowered to contribute. The selection process by Built In evaluated compensation, benefits, and various workplace attributes including remote work opportunities, DEI programs, and cultural offerings.

The company offers notable benefits including unlimited PTO, hybrid work options, and half-day Summer Fridays for U.S. employees. DH also provides extensive professional development opportunities through continuous learning, leadership development, and educational support programs. This recognition reflects the company's dedication to creating an environment where innovation and individual growth flourish while maintaining work-life balance.

Definitive Healthcare (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the 27th Annual Needham Growth Conference. CEO Kevin Coop and CFO Rick Booth will deliver a presentation on Wednesday, January 15, 2025, at 2:15 p.m. Eastern Time.

Definitive Healthcare reported Q3 2024 financial results with revenue of $62.7 million, a 4% decrease from Q3 2023. Net loss was $(187.8) million, including goodwill impairment charges of $228.2 million. Adjusted net income rose to $15.4 million from $14.6 million, while adjusted EBITDA fell 5% to $20.6 million. Cash flow from operations was $19.4 million, and unlevered free cash flow was $24.3 million. The company announced a $100 million stock repurchase program starting in 2025. Customer base grew to 530 enterprise clients. CFO Richard Booth will leave by June 1, 2025. Q4 2024 revenue guidance is $60.0-$61.0 million, adjusted net income $10.5-$11.5 million, and full-year 2024 revenue is expected to be $250.0-$251.0 million.

Definitive Healthcare (Nasdaq: DH) has scheduled its third quarter 2024 financial results announcement for Thursday, November 7, 2024, after market close. The healthcare commercial intelligence company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results. Investors can access the live audio webcast on the company's IR website and join via phone using domestic (877-358-7298) or international (+1-848-488-9244) dial-in numbers. A replay will be available until December 7, 2024.